organophosphonates has been researched along with trimetrexate in 3 studies
| Studies (organophosphonates) | Trials (organophosphonates) | Recent Studies (post-2010) (organophosphonates) | Studies (trimetrexate) | Trials (trimetrexate) | Recent Studies (post-2010) (trimetrexate) |
|---|---|---|---|---|---|
| 9,968 | 880 | 3,596 | 422 | 50 | 21 |
| Protein | Taxonomy | organophosphonates (IC50) | trimetrexate (IC50) |
|---|---|---|---|
| Dihydrofolate reductase | Mycobacterium avium | 0.3012 | |
| Dihydrofolate reductase | Homo sapiens (human) | 0.0207 | |
| Dihydrofolate reductase | Lacticaseibacillus casei | 0.1435 | |
| Dihydrofolate reductase | Saccharomyces cerevisiae S288C | 0.042 | |
| Dihydrofolate reductase | Escherichia coli K-12 | 0.1798 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.026 | |
| Dihydrofolate reductase | Pneumocystis carinii | 0.0378 | |
| Dihydrofolate reductase | Candida albicans | 0.04 | |
| Dipeptidyl peptidase 4 | Homo sapiens (human) | 0.01 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.008 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Toxoplasma gondii | 0.5788 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Trypanosoma cruzi | 0.0202 | |
| Dihydrofolate reductase | Rattus norvegicus (Norway rat) | 0.0794 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Diasio, RB; Stagg, MP | 1 |
| Ebbert, LP; Foley, JF; Gesme, DH; Hatfield, AK; Jett, JR; Krook, JE; Mailliard, JA; Maksymiuk, AW; Schreffler, DD; Su, JQ | 1 |
| Berry, DA; Cirrincione, C; Costanza, ME; Frei, E; Henderson, IC; McIntyre, OR; Norton, L; Schilsky, RL; Weiss, RB; Winer, E; Wood, WC | 1 |
1 review(s) available for organophosphonates and trimetrexate
| Article | Year |
|---|---|
Novel chemotherapeutic agents in early clinical development.
Topics: Adenine; Alkaloids; Anthraquinones; Antineoplastic Agents; Biphenyl Compounds; Camptothecin; Humans; Imides; Irinotecan; Isoquinolines; Naphthalimides; Neoplasms; Organophosphonates; Paclitaxel; Pyrazoles; Quinazolines; Sulfonylurea Compounds; Terpenes; Trimetrexate | 1990 |
3 trial(s) available for organophosphonates and trimetrexate
| Article | Year |
|---|---|
Novel chemotherapeutic agents in early clinical development.
Topics: Adenine; Alkaloids; Anthraquinones; Antineoplastic Agents; Biphenyl Compounds; Camptothecin; Humans; Imides; Irinotecan; Isoquinolines; Naphthalimides; Neoplasms; Organophosphonates; Paclitaxel; Pyrazoles; Quinazolines; Sulfonylurea Compounds; Terpenes; Trimetrexate | 1990 |
A randomized phase II trial of amonafide or trimetrexate in patients with advanced non-small cell lung cancer. A trial of the North Central Cancer Treatment Group.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Imides; Isoquinolines; Lung Neoplasms; Male; Middle Aged; Naphthalimides; Neoplasm Staging; Organophosphonates; Trimetrexate | 1993 |
Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642.
Topics: Adenine; Adult; Aged; Aminoglycosides; Analysis of Variance; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Imides; Isoquinolines; Melphalan; Middle Aged; Naphthalimides; Neoplasm Staging; Organophosphonates; Prospective Studies; Survival Analysis; Trimetrexate | 1999 |